Company Description Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases.
Proceeds Purposes This financing will fund the second of two pivotal trials of Reata’s lead product candidate, bardoxolone methyl (bardoxolone), in patients with advanced chronic kidney disease (CKD) and Type 2 diabetes.